The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
Reddit Stock: Why It May Finally Be Time to Buy the Dip The social media platform's underlying business is surging, and the stock's recent sell-off might be giving investors an attractive entry point.
Lucid Stock Is Cheap, but Does That Make It a Buy Now? Shares of Lucid have fallen 98% from their peak, which some may see as an opportunity, even though it also highlights material risk.
Prediction: Alphabet Stock Will Crush Palantir Stock Over the Next 5 Years Both Alphabet and Palantir are riding a massive wave of artificial intelligence demand, but a closer look at the two reveals a stark difference in their investment potential.
2 Defense Stocks to Buy in March Defense spending is on the rise around the world, and these two companies are set for some serious growth because of it.
Is Tesla a Recession-Proof Stock? Tesla sells cars -- and the auto industry is notoriously cyclical. But Tesla's structure and long-term strategy may give it more resilience than its peers.
2 No Brainer Energy Dividend Stocks to Buy As Oil Tops $100 Oil pushing toward $100 can make energy dividends look irresistible, but the best picks are the ones that don't need $100 oil to keep paying you. Here are two dividend giants that have already proven their payouts can hold up when the cycle turns.
2 Top Cybersecurity Stocks to Buy in March These companies boast strong sales and compelling share price valuations.
2 Energy Stocks to Consider Instead of Crude Oil Oil prices go up, and they go down; these high-yield energy businesses don't really care.
Is Nvidia Stock a Buy? Nvidia is riding a multiyear demand wave.
Why Nebius Stock Popped Today A blockbuster deal with an artificial intelligence (AI) giant has investors excited.
Starbucks vs. Nike: Which Dividend Stock Is a Better Buy? While both of these iconic consumer brands offer dividends, one stands out as the better buy today.
This Investor Sold $12 Million of a Momentum Bet, Signaling Cooling Appetite for High-Flying Stocks Invesco DWA Momentum ETF tracks a diversified portfolio of U.S. equities selected for strong relative strength characteristics.
What Investors Should Know About This $8 Million Tech ETF Sale Last Quarter This technology ETF tracks the NASDAQ-100 sector with an equal-weighted strategy, offering diversified exposure to large-cap tech equities.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
An nLIGHT Director Sold Company Shares Worth $1.6 Million. Is Now the Time to Buy or Sell the Stock? nLIGHT, a leader in advanced laser solutions for industry and defense, just reported a notable insider sale amid standout 1-year returns.
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
The Clock Is Ticking on Claiming the New Senior Tax Deduction Seniors get a generous new tax deduction, but there's only a limited time to claim it.
Why I'm Still Not Buying CoreWeave Stock CoreWeave is posting incredible top-line growth, but its staggering costs and capital requirements make the stock too speculative for my portfolio.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
Why Circle Internet Group Stock Crushed it on Monday Impressed by the take-up of the company's stablecoin, an analyst upgraded his recommendation to buy.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Why ServiceNow Stock Edged Past the Market Today An analyst raised his price target on the beleaguered tech stock.
Got $2,000? 2 Top Growth Stocks to Buy That Could Double Your Money. These beaten-down retail stocks could begin to grow on improved business performance and low valuations.
Down 20% From Its High, Is Tesla Stock a Buy Right Now? Competition has been intensifying in the electric vehicle market, and that has resulted in some lackluster results for Tesla in recent quarters.
What Is 1 of the Best AI Stocks to Own for the Next 10 Years? It's smart for investors to consider ways to build their portfolios with exposure to AI.
Why Nvidia Stock Just Dropped After Jumping Nearly 5% Nvidia's GTC conference delivered big news, but the stock couldn't hold onto its early gains.
1 Monster Energy Stock to Hold for the Next 20 Years (And Shares Are Still Under $50) Devon Energy is quietly building one of the most durable shareholder-return stories in U.S. shale: ultra-low production costs, billions in free cash flow, and a pending Coterra merger that could lift the dividend and supercharge buyback.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
SCHA Offers Larger Size and More Liquidity Than ISCB With similar costs but differences in size, sector focus, and liquidity, these ETFs offer distinct advantages for small-cap investors.
Stock Market Today, March 16: SoundHound AI Rises After Debuting On-Device Car Assistant at Nvidia GTC SoundHound AI rose after unveiling its Edge Agentic+ automotive assistant at Nvidia’s GTC conference, as investors assess how on-device AI could expand voice software adoption in vehicles.
Why Shiba Inu Keeps Going Up Shiba Inu has been gaining even as the stock market has been falling.
Will Costco Wholesale Stock Join the Trillion-Dollar Club by 2030? Costco's stock has been soaring in recent years, and it still possesses some attractive growth potential.
Why XRP Just Surged Past $1.50 XRP is rallied alongside the broader crypto market, with a new Mastercard partnership adding fuel.
Ulta Stock: Down 24% in Just 1 Month, Is This a Buying Opportunity? The beauty retailer delivered strong fourth-quarter sales, but a cautious outlook and shrinking margins have shifted the market's perspective.
Stock Market Today, March 16: Nasdaq Gains 1% Stocks on Easing Oil Prices and AI Optimism On March 16, 2026, cooling oil prices meant markets erased some of last week's losses today, though geopolitical risks lingered.
With the R2 SUV Officially Here, Is Rivian Stock a Buy? The R2 will be a key component in helping the company reach profitability.
Stock Market Today, March 16: Navitas Rises After Launching New SiC Power Chips for AI Data Centers Navitas rose after unveiling new silicon carbide power chips designed for AI data centers and energy infrastructure, as investors weighed the growing power demands of artificial intelligence systems.
